CINECA IRIS Institutional Research Information System

MOLINARO, ELEONORA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.127
EU - Europa 3.700
AS - Asia 651
AF - Africa 165
SA - Sud America 8
OC - Oceania 1
Totale 8.652
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.035
DE - Germania 1.452
IT - Italia 659
SE - Svezia 633
CN - Cina 307
GB - Regno Unito 274
BG - Bulgaria 219
AT - Austria 203
CI - Costa d'Avorio 92
SG - Singapore 89
CA - Canada 85
TR - Turchia 78
VN - Vietnam 71
RU - Federazione Russa 67
SN - Senegal 67
UA - Ucraina 59
FI - Finlandia 48
IN - India 40
HK - Hong Kong 20
BE - Belgio 17
CH - Svizzera 15
NL - Olanda 13
FR - Francia 10
JP - Giappone 9
PL - Polonia 9
IR - Iran 8
GR - Grecia 7
KR - Corea 6
MG - Madagascar 5
MX - Messico 5
BR - Brasile 4
IL - Israele 4
AR - Argentina 3
AZ - Azerbaigian 3
CY - Cipro 3
ID - Indonesia 3
IE - Irlanda 3
RS - Serbia 3
MY - Malesia 2
PH - Filippine 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
AU - Australia 1
BY - Bielorussia 1
DK - Danimarca 1
EG - Egitto 1
ES - Italia 1
GE - Georgia 1
HR - Croazia 1
HU - Ungheria 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
MN - Mongolia 1
NO - Norvegia 1
PT - Portogallo 1
SA - Arabia Saudita 1
TH - Thailandia 1
VE - Venezuela 1
Totale 8.652
Salva come PNG Salva come JPEG
Città #
Woodbridge 515
Fairfield 441
Chandler 419
Ashburn 312
Ann Arbor 311
Houston 270
Sofia 219
Milan 208
Seattle 203
Vienna 190
Cambridge 171
Wilmington 161
New York 160
Beijing 123
Princeton 104
Abidjan 92
Lawrence 83
Ottawa 78
Jacksonville 68
Dakar 67
Medford 61
Florence 58
Izmir 58
London 53
Pisa 50
Serra 46
Bremen 45
Dearborn 43
Frankfurt am Main 42
Des Moines 40
Nanjing 40
Dong Ket 36
San Diego 32
Rome 24
Boulder 23
Redwood City 20
Los Angeles 19
Redmond 19
Hong Kong 18
Lancaster 18
Nanchang 17
Nürnberg 17
Brussels 16
Bern 13
Changsha 13
Norwalk 12
Jüchen 11
Kunming 11
Washington 11
Jiaxing 10
Ogden 10
Düsseldorf 9
Hefei 9
Pune 9
Tianjin 8
Chicago 7
Guangzhou 7
Istanbul 7
Scandicci 7
Vicopisano 7
Chengdu 6
Falls Church 6
Hebei 6
Ningbo 6
Shenyang 6
Singapore 6
Zhengzhou 6
Antananarivo 5
Boardman 5
Hangzhou 5
Marseille 5
Samsun 5
Shanghai 5
Tokyo 5
Toronto 5
Grafing 4
Kocaeli 4
Parma 4
San Francisco 4
Tehran 4
Wuhan 4
Atakum 3
Bengaluru 3
Civitanova Marche 3
Council Bluffs 3
Detroit 3
Duncan 3
Jinan 3
Naples 3
Palermo 3
Pontedera 3
San Martino In Strada 3
Veracruz 3
Verona 3
Ypsilanti 3
Amsterdam 2
Angri 2
Auburn Hills 2
Bangalore 2
Baotou 2
Totale 5.309
Salva come PNG Salva come JPEG
Nome #
Surgical treatment of low- and intermediate-risk papillary thyroid cancer with minimally invasive video-assisted thyroidectomy 258
ALL-TRANS RETINOIC ACID TREATMENT INHIBITS THE GROWTH OF RARb mRNA EXPRESSING THYROID CANCER CELL LINES BUT DOES NOT RE-INDUCE THE EXPRESSION OF THYROID SPECIFIC GENES 191
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line. 189
Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. 185
The presence of a tall cells>10% in a classical variant of papillary thyroid carcinoma (CV-PTC) makes its aggressiveness similar to that of tall cell variant (TCV-PTC) 174
Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients 170
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line 158
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies 156
Targeted Therapy in Thyroid Cancer: State of the Art 150
All-trans Retinoic Acid treatment inhibits the growth of RARb mRNA expressing thyroid cancer cell lines but does not re-induce the expression of thyroid specific genes 146
null 146
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 146
Changing Trend of Thyroglobulin Antibodies in Patients with Differentiated Thyroid Cancer Treated with Total Thyroidectomy Without ¹³¹I Ablation 143
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 141
Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients 136
Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal 135
Prevalence of papillary thyroid cancer (PTC) in patients affected by medullary thyroid cancer (MTC) 134
RET point mutations in Thyroid Carcinoma 132
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) 132
Nuove indicazioni all’impiego del TSH umano ricombinante (rhTSH) e basse attività di 131I nella radioablazione del residuo tiroideo post-chirurgico. 123
Il carcinoma tiroideo: nuove prospettive terapeutiche. 120
Ret Genetic Screening in Patients with Medullary Thyroid Cancer and Their Relatives: Experience with 807 Individuals at One Center 119
Lung recurrence of papillary thyroid cancer diagnosed with antithyroglobulin antibodies after 10 years from initial treatment. 119
Thyroid consequences of the Chernobyl nuclear accident. 117
Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato 116
Recombinant human TSH (rhTSH) in 2009: new perspectives in diagnosis and therapy 115
Thyroid autoantibodies and thyroid function in subjects exposed to Chernobyl fallout during childhood: evidence for a transient radiation-induced elevation of serum thyroid antibodies without an increase in thyroid autoimmune disease. 115
null 114
The stage of differentiated thyroid cancer at diagnosis is significantly more advanced in children than in adolescent 111
ROLE OF THYROID REMNANT ABLATION WITH LOW ACTIVITY OF 131I IN PATIENTS WITH LOW AND INTERMEDIATE RISK PAPILLARY THYROID CARCINOMA (PTC). 110
Failure to use measurement of megalin secretory components complexed with serum thyroglobulin as a tool to identify metastases after surgery in papillary thyroid cancer. 109
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 109
In vitro studies of retnoic acid treatment of human anaplastic, poorly differentiated papillary, follicular and medullary thyroid cancer cell lines 108
Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma 108
Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma 108
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center 108
null 107
Vandetanib and the predictive factors of durable response in locally advanced or metastatic medullary thyroid cancer: a single center experience. 107
Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. 105
null 105
null 103
Clinically unpredictable prognostic factors in the outcome of medullary thyroid cancer 100
Advantages and disadvantages of prophylactic central compartment lymph node dissection for differentiated thyroid cancer: the first randomized controlled study from a single referral center. 100
The Molecular Signature More Than the Site of Localization Defines the Origin of the Malignancy 100
Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow up of differentiated thyroid cancer patients 99
A rare adverse event (AE) in a group of radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients in therapy with lenvatinib. 99
BRAFV600E mutation is an indipendent predictive prognostic factor for persistent/recurrent disease in low risk differentiated Thyroid cancer patients: a 5 year follow-up study. 98
Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for ret gene mutations 93
mRECIST criteria to assess recurrent thyroid carcinoma treatment response after radiofrequency ablation: a prospective study 93
Lenvatinib treatment in the real clinical practice of progressive, radioiodine-refractory differentiated thyroid carcinoma: analysis of a big series followed in a single center 91
Studi in vitro del trattamento con acido retinico di linee di carcinoma tiroideo umano anaplastico, poco differenziato, follicolare e midollare 90
DIAGNOSTIC AND THERAPEUTIC ROLE OF THYROID REMNANT ABLATION WITH LOW ACTIVITY OF 131I IN PATIENTS WITH LOW AND INTERMEDIATE RISK PAPILLARY THYROID CARCINOMA (PTC). 90
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 89
Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. 88
Potential impact of BMI on the aggressiveness of presentation and clinical outcome of Differentiated Thyroid Cancer 87
Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up 85
Carcinoma tiroideo e gravidanza. 84
null 84
Thyroglobulin changes are highly dependent on TSH in low-risk DTC patients not treated with 131I 83
Clinical impact of molecular techniques for the presurgical diagnosis of differentiated thyroid cancer diagnosis 81
Radioiodine remnant ablation (RRA) Impact on the dynamic risk of restratification in the short-term follow-up of patients with differentiated thyroid cancer (DTC). 81
Lenvatinib Administered via Nasogastric Tube in Poorly Differentiated Thyroid Cancer 78
Significato prognostico della mutazione di BRAF in pazienti affetti da carcinoma papillare della tiroide con follow-up di 20 anni. 77
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH 77
Low-Risk Differentiated Thyroid Cancer with BRAFV600E mutation is more difficult to cure than negative cases: a 5-year follow-up study. 76
Ablazione del residuo tiroideo post chirurgico con rhTSH e 30 mCi. 72
null 70
Use of low-dose radioiodine ablation for Graves’ orbitopathy: results of a pilot, perspective study in a small series of patients 63
Ca19.9 positivity and doubling time are prognostic factors of mortality in patients with advanced medullary thyroid cancer with no evidence of structural disease progression according to RECIST 62
Single thyroid nodule 60
Impact of the Stimulation method Used for 131-Therapy in Patients With Differentiated Thyroid Cancer. 57
Management of thyrotoxicosis induced by PD1 or PD-L1 blockade 57
Impact of Advanced Age on the Clinical Presentation and Outcome of Sporadic Medullary Thyroid Carcinoma 56
Non thyroidal second primary malignancies in differentiated thyroid cancer patients: is the incidence increased comparing to the general population and could it be a radioiodine therapy consequence? 51
OR21-01 Pre-Operative Calcitonin Value as a Predictive Factor of Cancer Related Death in Sporadic Medullary Thyroid Carcinoma 49
The outcome of metastatic differentiated thyroid cancer is similar in patients prepared for 131-I therapy with recombinant TSH or Hypothyroidism. 49
Follicular (FVPTC) VS Classical (CVPTC) variant of papillary thyroid cancer: correlation of the outcome after 12 years of follow up. 49
Assessing mPTC Progression during Active Surveillance: Volume or Diameter Increase? 49
Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates 44
A novel fusion RET/PTC3 involving NCOA4 and RET genes in a pediatric case of Papillary Thyroid Carcinoma 43
The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study 37
Il carcinoma della tiroide 33
Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer 33
Yttrium-90 transarterial radioembolization for liver metastases from medullary thyroid cancer 31
Correction to: Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer (Journal of Endocrinological Investigation, (2021), 44, 10, (2139-2151), 10.1007/s40618-020-01491-3) 31
Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up. 29
Papillary thyroid microcarcinoma: Toward an active surveillance strategy 23
Detection of metastases from differentiated thyroid cancer by different imaging techniques (neck ultrasound, computed tomography and [18F]-FDG positron emission tomography) in patients with negative post-therapeutic 131I whole-body scan and detectable serum thyroglobulin levels. 20
Ret Oncogene and Thyroid Carcinoma 20
Tall cell percentage alone in PTC without aggressive features should not guide patients’ clinical management 20
Effect of Pregnancy and Menopause on Micropapillary Thyroid Carcinomas During Active Surveillance 18
How to manage patients with differentiated thyroid cancer and a rising serum thyroglobulin level. 17
Radio-iodine refractory thyroid cancer patients: a tailored follow-up based on clinicopathological features 16
The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 Years experience at one single center 15
Significance of Thyroglobulin Autoantibodies in Patients With Thyroid Cancer Treated With Lenvatinib 7
Active surveillance in differentiated thyroid cancer: a strategy applicable to all treatment categories response 7
Predictive factors for central neck compartment lymphnodes metastases' in sporadic medullary thyroid cancer patients 6
Management of patients with extensive locally advanced thyroid cancer: results of multimodal treatments 4
Fifty Years after the First Description, MEN 2B Syndrome Diagnosis Is Still Late: Descriptions of Two Recent Cases 4
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations 1
Totale 8.804
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.093
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.093
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019338 0 0 0 0 0 0 0 0 0 0 200 138
2019/20201.843 190 97 120 114 197 197 202 116 144 186 248 32
2020/2021665 106 29 93 28 46 64 41 41 47 51 28 91
2021/20221.040 31 36 12 81 223 129 39 42 57 54 63 273
2022/20231.774 214 295 165 149 159 189 33 119 320 12 108 11
2023/2024965 111 112 143 67 133 205 87 50 12 20 25 0
Totale 8.804